The Alphabet Soup of Hematologic Disorders: Background and Treatment Updates in ITP, TTP, HUS, and DIC

Tuesday, December 6, 2022

2:00 PM – 4:00 PM

Location: Mandalay Bay South Convention Center, Mandalay Bay D, Level 2

CE Credits: 2.00 contact hours

Planned in cooperation with the American College of Clinical Pharmacy
Activity #: 0217-9999-22-071-L01-P
Activity Type: Application-based
Target Audience: Pharmacist

This session will provide a foundation for the basic pathophysiology, etiology, and diagnosis of hematologic disorders including immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC). The critical role of the pharmacist in the treatment of each disease state will be elucidated. The context of these disorders in the setting of COVID-19 and vaccine-associated sequelae will be explored. Pharmacists and pharmacy learners who do not have expertise in Hematology practice will gain confidence in their diagnosis and management skills. Additionally, this session is meant to offer late-breaking updates in the treatment of hematologic disorders for Hematology/Oncology pharmacists in practice.

This activity is approved for Board Certified Oncology Pharmacist (BCOP) recertification credit.

Learning Objectives:

Illustrate understanding of the basic pathophysiology of immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC) and their associated drug therapies.
Examine patients’ medication lists to identify common medications (including cancer treatments, immunotherapies, and drugs from other classes) implicated in the development of bleeding disorders.
Compare and contrast pharmacologic standard-of-care and new therapies for the treatment of immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC).
Show the relationship between COVID-19 (and COVID-19 vaccinations) and bleeding disorders, and how to approach the treatment of these disorders.
Demonstrate the critical role of the clinical pharmacist in the procurement and administration of pharmacologic therapies used to treat bleeding disorders.

Program Chair(s)

Sarah Maryon Hayes, PharmD, BCOP

Hematology/Oncology Clinical Pharmacy Specialist
North Memorial Health

Moderator(s)

Sarah Maryon Hayes, PharmD, BCOP

Hematology/Oncology Clinical Pharmacy Specialist
North Memorial Health

Faculty Member(s)

Sebastian Cerdeña, PharmD, BCOP

Oncology Clinical Pharmacy Specialist
Barnes Jewish Hospital
Kathryn Dane, PharmD

Clinical Pharmacy Specialist, Benign Hematology and Cardiology
The Johns Hopkins Hospital
Sarah Maryon Hayes, PharmD, BCOP

Hematology/Oncology Clinical Pharmacy Specialist
North Memorial Health